SCHEMBL5224650

SCHEMBL5224650

CCc1nn(CCO)c(CC)c1Oc1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
PTGDR2 Q9Y5Y4 5/20 0.37
BRD4 O60885 1/20 0.36
BRD2 P25440 1/20 0.36
BRD3 Q15059 1/20 0.36
CREBBP Q92793 1/20 0.36
NPBWR1 P48145 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAPT P10636 1/20 0.35
ENPP3 O14638 1/20 0.35
ALPL P05186 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509302 0.87 PTGDR2 (0.38) PGRALDH1A1PTGDR2BRD4BRD2
SCHEMBL5228272 0.86 PTGDR2 (0.36) PGRKMT2AALDH1A1PTGDR2NPBWR1
SCHEMBL5228227 0.85 PTGDR2 (0.40) CYP1A2CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL4097849 0.84 PGR (0.59) PGRKDM4E
SCHEMBL5226171 0.83 FPR2 (0.41) PGRLMNASMN1; SMN2PTGDR2MAPT
SCHEMBL5227746 0.83 PTGDR2 (0.42) LMNAALDH1A1PTGDR2BRD4BRD2
SCHEMBL5230979 0.82 KCNH2 (0.36) PGRPTGDR2BRD4BRD2BRD3
SCHEMBL5229746 0.82 P2RX7 (0.37) KMT2APTGDR2
SCHEMBL5227964 0.81 PTGDR2 (0.42) PGRCYP1A2KMT2ALMNAALDH1A1
SCHEMBL4107983 0.81 AR (0.42) PGRNPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100408564-C Pyrazole derivatives for treating HIV PFIZER LTD (US) 2008-08-06 CN claimed
EP-1377556-B1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LTD (GB) 2007-04-04 EP claimed
EP-1762567-A1 Pyrazole derivatives for treating HIV Pfizer Limited (GB) 2007-03-14 EP claimed
CN-1514828-A Pyrazole derivatives for treating HIV 2004-07-21 CN claimed
EP-1377556-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV Pfizer Limited (GB) 2004-01-07 EP claimed
US-20030100554-A1 Pyrazole derivatives JONES LYN HOWARD (GB) 2003-05-29 US claimed
WO-2002085860-A1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LIMITED (GB) 2002-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100554-A1 Pyrazole derivatives REV1, SARS1, CYP2F1 PGR 1045/4885CYP1A2 173/4885CYP2D6 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.